Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2009
08/27/2009US20090215823 Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor
08/27/2009US20090215822 Substituted Oxadiazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate Receptors
08/27/2009US20090215821 N-Substituted Azacycles
08/27/2009US20090215820 Novel alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
08/27/2009US20090215819 Anti-infective and immunomodulatory compounds
08/27/2009US20090215818 Thiozolidinedione derivatives as pi3 kinase inhibitors
08/27/2009US20090215817 Novel Triazolopyridine Compounds for the Treatment of Inflammation
08/27/2009US20090215816 Imidazo(1,2-a)Pyridine Derivatives Useful as Peptide Deformylase (PDF) Inhibitors
08/27/2009US20090215815 Neurotrophin antagonist compositions
08/27/2009US20090215814 Method of inhibiting neurotrophin-receptor binding
08/27/2009US20090215813 Histone deacetylase inhibitors as immunosuppressants
08/27/2009US20090215812 Biomarkers for evaluating likelihood of tumor sensitivity to an mtor inhibitor
08/27/2009US20090215811 Novel Pharmaceutical Composition and Its Use in a Method For Treatment of Patients With Upper Respiratory Mucosal Congestion
08/27/2009US20090215810 Method to Treat Premature Ejaculation in Humans
08/27/2009US20090215809 crystalline calcium (3S)-{[(1R)-isobutanoyloxyethoxy]carbonylaminomethyl}-5-methyl-hexanoate hydrate; sustained release oral dosage formualtion with opioid agonist, selective serotonin re-uptake inhibitor and noradrenaline re-uptake inhibitor; an inflammatory disease, neuropathic pain, anxiety, psychosis
08/27/2009US20090215808 Oral pharmaceutical dosage forms
08/27/2009US20090215807 Novel Diazaspiroalkanes and Their Use for Treatment of CCR8 Mediated Diseases
08/27/2009US20090215806 Rosuvastatin calcium with a low salt content
08/27/2009US20090215805 4-Heteroaryl Pyrimidine Derivatives and use thereof as Protein Kinase Inhibitors
08/27/2009US20090215804 Fumarate of 4- [[4- [[4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino] -2-pyrimidinyl]amino]benzonitrile
08/27/2009US20090215803 Pyrimidinones as Casein Kinase II (CK2) Modulators
08/27/2009US20090215802 Deuterium-enriched lapatinib
08/27/2009US20090215801 Novel 2-Aminopyrimidinone Derivatives And Their Use
08/27/2009US20090215800 Enzyme and Receptor Modulation
08/27/2009US20090215799 Heterocyclic substituted bisarylurea derivatives
08/27/2009US20090215798 Inhibitor Compounds
08/27/2009US20090215796 Compositions, Kits and Methods for a Titration Schedule for Pardoprunox Compounds
08/27/2009US20090215795 Cyclic amidine derivatives
08/27/2009US20090215794 piperazine derivatives such as (R)-4-cyano-N-{2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)piperazine-1-yl]-propyl}-N-pyridin-2-yl-benzamide, useful as serotonin receptor antagonists, used for the treatment of nervous system disorders, Parkinson's disease, Tourette's syndrome, headache and autism
08/27/2009US20090215793 Methods for treating drug resistant cancer
08/27/2009US20090215792 Method of treating chronic myelogenous leukemia cells
08/27/2009US20090215791 New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine
08/27/2009US20090215790 Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof
08/27/2009US20090215789 Cyclic hexadepsipeptides, processes for their production and their use as pharmaceuticals
08/27/2009US20090215788 Pyrrolopyrazine kinase inhibitors
08/27/2009US20090215787 Preparations of new polymorphic forms of varenicline tartrate
08/27/2009US20090215786 Novel cysteine protease inhibitors and their therapeutic applications
08/27/2009US20090215785 Pyrrolopyrazine kinase inhibitors
08/27/2009US20090215784 Maleate Salts of 6-(5-Chloro-2-Pyridyl)-5-[(4-Methyl-1-Piperazinyl)Carbonyloxy]-7-oxo-6,7-dihydro-5H-Pyrrolo[3,4-b]Pyrazine
08/27/2009US20090215783 Composition for induction or inhibition of stem cell differentiation
08/27/2009US20090215782 Use of PDE-5 Inhibitors for Endothelial Repair of Tissues Impaired by Trauma or Disease
08/27/2009US20090215781 Alpha-helix mimetics and methods relating to the treatment of fibrosis
08/27/2009US20090215780 Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity
08/27/2009US20090215779 Oxadiazole derivatives as dgat inhibitors
08/27/2009US20090215778 Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives
08/27/2009US20090215777 Pyrimidine Derivatives As HSP90 Inhibitors
08/27/2009US20090215776 Organic compounds
08/27/2009US20090215775 Sulphonamido-Substituted Cyclohexyl Sulphones for Treatment of Cancer
08/27/2009US20090215774 Uses of indane compounds
08/27/2009US20090215773 Dihydropyridine derivatives
08/27/2009US20090215772 Hydroxybenzamide derivatives and their use as inhibitors of HSP90
08/27/2009US20090215771 Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation
08/27/2009US20090215770 Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases
08/27/2009US20090215769 Use of soluble guanylate cyclase activators for the treatment of Raynaud's Phenomenon
08/27/2009US20090215768 Isoxazole derivatives and pharmaceutical compositions comprising the same
08/27/2009US20090215767 Isoflavone derivatives and pharmaceutical compositions comprising the same
08/27/2009US20090215766 Tetracyclic inhibitors of janus kinases
08/27/2009US20090215765 Neuroprotective compounds for treating optic neuropathies
08/27/2009US20090215764 Antimicrobial agents
08/27/2009US20090215763 Substituted benzoxazinones
08/27/2009US20090215762 Siloxane polymer containing tethered levofloxacin
08/27/2009US20090215761 Quinobenzoxazine analogs and methods of using thereof
08/27/2009US20090215759 Modulators for amyloid beta
08/27/2009US20090215758 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs
08/27/2009US20090215757 Process for Preparation of High-Purity Meloxicam and Meloxicam Potassium Salt
08/27/2009US20090215756 Formulations containing losartan and/or its salts
08/27/2009US20090215755 Use of a pyrazole derivative for preparing medicinal products that are useful in the prevention and treatment of dyslipidaemias and of diseases related to dyslipidaemias and/or to obesity
08/27/2009US20090215754 Methods and compositions for the treatment of neuropsychiatric and addictive disorders
08/27/2009US20090215753 Topical Compositions for Paediatric Use
08/27/2009US20090215752 Compounds, preparation and therapeutic use thereof
08/27/2009US20090215751 Use of Selective Chloride Channel Modulators to Treat Alcohol and/or Stimulant Substance Abuse
08/27/2009US20090215750 Pyrrolopyrazine kinase inhibitors
08/27/2009US20090215749 Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor
08/27/2009US20090215748 FXR agonists for treating vitamin D associated diseases
08/27/2009US20090215747 Heterocyclic compounds as inhibitors of beta-lactamases
08/27/2009US20090215746 Substituted pyrazolo[1,5-a]pyrimidines as calcium receptor modulating agents
08/27/2009US20090215745 Association of a sinus node If current inhibitor and a calcium inhibitor, and pharmaceutical compositions containing it
08/27/2009US20090215744 Solid Formulations
08/27/2009US20090215743 Tricyclic benzazepine derivatives and their use
08/27/2009US20090215742 Amide resorcinol compounds
08/27/2009US20090215741 1H-Pyrimido[4,5-b]indole Derivatives, Their Preparation and Therapeutic Use
08/27/2009US20090215740 Therapeutic substituted beta-lactams
08/27/2009US20090215739 Chemical method of making a suspension, emulsion or dispersion of pyrithione particles
08/27/2009US20090215738 Prevention and treatment of an increase in cardiovascular risk, adverse cardiovascular events, infertility, and adverse psychological effects after androgen or gnrh analogue intake
08/27/2009US20090215737 Pharmaceutical Compositions - 2
08/27/2009US20090215736 inhibitors of apoptosis and IL-1 beta secretion; mediate cell apoptosis and inflammation; good cell penetration and pharmacokinetic properties; [3S/R(2S)]3-[2-(Carbazol-9-yl-2-oxo-ethyl)-pentanoylamino]-5-fluoro-4-oxo-pentanoic acid
08/27/2009US20090215735 Topical solution formulations containing a corticosteroid and a cyclodextrin
08/27/2009US20090215734 Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
08/27/2009US20090215733 Therapy for the prophylaxis or treatment of adverse body composition changes and/or decreased muscle strength after androgen or gnrh analogue intake
08/27/2009US20090215732 Combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma
08/27/2009US20090215731 Reduction of Side Effects From Aromatase Inhibitors Used for Treating Breast Cancer
08/27/2009US20090215730 Antineoplastic compounds and pharmaceutical compositions thereof
08/27/2009US20090215729 Microparticle compositions to modify cancer promoting cells
08/27/2009US20090215728 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
08/27/2009US20090215727 Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphate and vitamin b6 related compounds
08/27/2009US20090215726 Phosphono-Pent-2-en-1-yl Nucleosides and Analogs
08/27/2009US20090215725 Substituted 4-aminocyclohexane derivatives
08/27/2009US20090215724 Pyrrolopyrazine kinase inhibitors
08/27/2009US20090215723 Organic silicic acids complex for therapeutic and cosmetic applications
08/27/2009US20090215722 Dextran; inhibit rejection of transplanted cells by the immune system of the recipient; gene therapy; saturating the antigen presenting cells (APC's) with nonimmunogenic agents; readily phagocytosed by APCs
1 ... 2600 2601 2602 2603 2604 2605 2606 2607 2608 2609 2610 2611 2612 2613 2614 2615 2616 2617 2618 2619 2620 ... 7860